Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the objective response rate (ORR; confirmed complete response(CR) or partial response (PR)) of gefitinib using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in Caucasian patients with EGFR M+ NSCLC (activating sensitising Epidermal Growth Factor Receptor EGFR mutation postive (EGFR M+))
Critère d'inclusion
- non-small cell lung cancer